共 50 条
- [21] A phase 1/2 study of retifanlimab (INCMGA00012, Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) combination therapy in patients (Pts) with advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Hamid, OmidGutierrez, MartinMehmi, InderjitDudzisz-Sledz, MonikaHoyle, Paul EdwardWei, WendyPowderly, John D.
- [22] Phase I Study of Androgen Deprivation Therapy in Combination with Anti-PD-1 in Melanoma Patients Pretreated with Anti-PD-1CLINICAL CANCER RESEARCH, 2023, 29 (05) : 858 - 865Robert, CarolineLebbe, CelesteLesimple, ThierryLundstrom, EijaNicolas, ValerieGavillet, BrunoCrompton, PhilippaBaroudjian, BarouyrRoutier, EmilieLejeune, Ferdy J.
- [23] PHASE I STUDY OF INTRATUMORAL NBTXR3 IN COMBINATION WITH ANTI-PD-1 IN PATIENTS WITH ADVANCED CANCERSJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A249 - A249Shen, ColetteFrakes, JessicaNiu, JiaxinWeiss, JaredCaudell, JimmyJameson, KatherineSaid, PatriciaSeiwert, Tanguy
- [24] Single-cell characterization of anti-LAG-3 and anti- PD-1 combination treatment in patients with melanomaJOURNAL OF CLINICAL INVESTIGATION, 2023, 133 (06):Huuhtanen, JaniKasanen, HennaPeltola, KatriinaLonnberg, TapioGlumoff, VirpiBruck, OscarDufva, OlliPeltonen, KaritaVikkula, JohannaJokinen, EmmiIlander, MetteLee, Moon HeeMakela, SiruNyakas, MartaLi, BinHernberg, MicaelaBono, PetriLahdesmaki, HarriKreutzman, AnnaMustjoki, Satu
- [25] A phase I study of Sym021, an anti-PD-1 antibody (Ab), alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)ANNALS OF ONCOLOGY, 2019, 30 : 488 - +Spreafico, A.Janku, F.Rodon, J. A.Tolcher, A. W.Chandana, S. R.Oliva, M.Musalli, S.Knauss, L.Kragh, M.Alifrangis, L.Frohlich, C.Melander, M. C.Blondal, T.Pedersen, M. W.Lantto, J.Wood, D.Nadler, P. I.Horak, I. D.Siu, L. L.Lakhani, N.
- [26] Phase Ia/Ib dose-escalation study of IBI110 (anti-LAG-3 mAb) as a single agent and in combination with sintilimab (anti-PD-1 mAb) in patients (pts) with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Zhou, CaiHe, YayiRen, ShengxiangLi, WeiZhu, JunYu, JiaWang, LeiXiong, AnwenXu, NongMao, ChenyuPan, BeiqingLiu, YingZhou, Hui
- [27] Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody toripalimab, in patients with advanced malignant tumors: A phase Ib/II, open-label, multicenter, dose escalation/expansion studyCANCER RESEARCH, 2024, 84 (07)Yang, YunpengZhao, YuanyuanFang, WenfengHuang, YanZhang, YaxiongBa, YiWang, ZhenDeng, ChaoHu, DeshengWang, WeiLi, GuilingLuo, SuxiaFu, ZhichaoZhu, HaishengWang, HuiliZhao, ShiweiLi, TaoCai, CharlesZhang, Li
- [28] Cemiplimab, a Human Monoclonal Anti-PD-1, Alone or in Combination with Radiotherapy: Phase 1 NSCLC Expansion CohortsJOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S366 - S366Moreno, V.Gil-Martin, M.Johnson, M.Aljumaily, R.Lopez-Criado, M. P.Northfelt, D.Crittenden, M.Jabbour, S.Rosen, L.Calvo, E.Papadopoulos, K.Garrido, P.Hervas Moron, A.Rietschel, P.Mohan, K.Li, J.Stankevich, E.Feng, M.Lowy, I.Fury, M.
- [29] A phase 2, randomized, open-label study of gemcitabine/cisplatin plus cemiplimab (REGN2810, anti-PD-1) with or without fianlimab (REGN3767, anti-LAG-3) for organ preservation in patients with localized muscle-invasive bladder cancer (NeoSTOP-IT).JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : TPS882 - TPS882Wei, Alexander Z.Bakir, BasilLenis, Andrew T.Anderson, Christopher B.Runcie, KarieDecastro, Guarionex JoelPan, Samuel S.Shen, Michael M.Mckiernan, James M.Stein, Mark N.
- [30] Phase I studies of Sym021, an anti-PD-1 antibody, alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)ANNALS OF ONCOLOGY, 2020, 31 : S704 - S704Lakhani, N.Spreafico, A.Tolcher, A. W.Rodon, J.Janku, F.Chandana, S. R.Oliva, M.Sharma, M.Abdul-Karim, R. M.Hansen, U. H.Hansen, L.Skartved, N. J. O.Poulsen, T. T.Nadal, R. P.Lantto, J.Wood, D. L.Nadler, P. I.Siu, L. L.